You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK):達伯舒®(信迪利單抗注射液)成功新增三項一線適應症納入國家醫保目錄
格隆匯 12-03 12:13

格隆匯12月3日丨信達生物(01801.HK)宣佈,根據國家醫療保障局的最新公吿,集團與禮來製藥共同開發的創新PD-1抑制劑達伯舒®(信迪利單抗注射液)已獲批所有適應症成功納入新版《國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年版)》(”國家醫保目錄“)乙類範圍。新版醫保目錄將於2022年1月1日起正式實施。

該次達伯舒®(信迪利單抗注射液)已獲批所有四項適應症均成功納入新版國家醫保目錄,其中三大適應症首次納入醫保目錄:

● 達伯舒®聯合培美曲塞和鉑類化療用未經系統治療的表皮生長因數受體(EGFR)基因突變陰性和間變性淋巴瘤激酶(ALK)陰性的晚期或複發性非鱗狀非小細胞肺癌(”nsqNSCLC“)的一線治療;

● 達伯舒®聯合吉西他濱和鉑類化療用不可手術切除的晚期或複發性鱗狀非小細胞肺癌(”sqNSCLC“)的一線治療;

● 達伯舒®聯合達攸同®(貝伐珠單抗注射液)用既往未接受過系統治療的不可切除或轉移性肝細胞癌(”HCC“)的一線治療。

另外,達伯舒®至少經過二線系統化療的復發或難治性經典型霍奇金淋巴瘤的適應症”cHL2019年首次納入國家醫保目錄,今年成功續約。

目前,達伯舒®(信迪利單抗注射液)成為國內唯一一個擁有包含一線非鱗非小細胞肺癌、一線鱗狀非小細胞肺癌、一線肝癌及霍奇金淋巴瘤在內的四項適應症獲批,並均被納入國家醫保的PD-1抑制劑。

公司表示,其將一如既往地支持國家深化醫療保障改革,積極迴應各級政府部門的相關工作,配合醫保政策在各統籌地區落地,進一步提高這款高品質免疫抗癌療法的可及性,減輕國內腫瘤患者和其家庭的經濟負擔。公司也將持續投入創新,踐行”開發出老百姓用得起的高品質生物“使命,提升藥物可負擔性和可及性,為實現”健康中國2030“目標不懈努力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account